Drug Trial News

RSS

Genzyme completes study on Sevelamer Carbonate in patients with chronic kidney disease

Genzyme has announced that a recently completed study of Renvela (sevelamer carbonate) achieved its primary endpoint, demonstrating a statistically significant reduction in serum phosphorus for hyperphosphatemic patients with chronic kidney disease who are not on dialysis.

17 Apr 2007

Geisinger Health System launches study on obesity and related liver problem

Relying on one of the largest collections of liver tissue samples ever acquired by a single organization, Geisinger Health System researchers have embarked on a massive study of one of the fastest growing liver problems.

17 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Eating cured meats increases the odds of developing chronic obstructive pulmonary disease

Frequent consumption of cured meats results in lower lung function test scores and increases the odds of developing chronic obstructive pulmonary disease (COPD), according to a large cross-sectional survey of adults in the U.S.

17 Apr 2007

Effect of alcohol and aspirin consumption in traumatic brain injury patients

An estimated 1.5 million people in the United States incur a traumatic brain injury (TBI) every year and 60,000 people die annually from these injuries.

17 Apr 2007

Access to dermatologist improves melanoma-related health outcomes

Individuals whose melanoma is diagnosed by a dermatologist may be more likely to have early-stage cancer and to survive five years than those with melanoma diagnosed by a non-dermatologist, according to a report in the April issue of Archives of Dermatology.

17 Apr 2007

Peregrine's selective anti-VEGF antibodies shown to be as effective as Avastin

Peregrine Pharmaceuticals has reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer.

17 Apr 2007

Potential treatments for mouth ulcers

The drug pentoxifylline appears to have limited benefit in the first-line treatment of mouth ulcers due to recurrent apthous stomatitis, according to a report in the April issue of Archives of Dermatology.

17 Apr 2007

Mellowing with age helps you live longer!

While mellowing with age has often been thought to have positive effects, a Purdue University researcher has shown that doing so could also help you live longer.

17 Apr 2007

Cetuximab improves survival and slows progression of colorectal cancer

Research presented at the 2007 Annual Meeting of the American Association for Cancer Research confirmed that there is now an effective treatment option for colorectal cancer patients for whom all other treatment options have been exhausted, cetuximab.

17 Apr 2007

Diets high in bacon, ham and hot dogs bad for the lungs

A study by researchers in the U.S. has found that cured meats such as bacon, ham, and hot dogs can cause lung damage.

17 Apr 2007

Chondroitin for arthritis just doesn't work

According to Swiss researchers the dietary supplement chondroitin is no better than a placebo at easing the hip and knee pain of arthritis and they believe its use should be discouraged.

17 Apr 2007

Factors that influence late stage cancer diagnosis

Researchers from the Keck School of Medicine of the University of Southern California (USC) found that patients who received a later stage cancer diagnosis were likely to be living in an unsafe neighborhood, using public transportation and traveling at least 45 minutes to get to a doctor's office.

16 Apr 2007

Socio-ecological and cultural factors attributed to later stage cancer diagnosis

16 Apr 2007

Snake venom toxin as a treatment for prostate cancer

This certainly sounds unusual, but Dr. Son and colleagues report on the effectiveness of the snake venom toxin (SVT) Vipera lebetina turanica in the inhibition of androgen-independent prostate cancer (AICAP) in the February 2007 issue of Molecular Cancer Therapeutics .

16 Apr 2007

New chemical agent, MCP110, provides synergistic effect to standard drugs

Integrating the use of drugs targeted to specific cancer proteins into current chemotherapy regimens to improve the efficacy of systemic treatment is an important clinical goal at Fox Chase Cancer Center.

16 Apr 2007

Chaetocin shows promise as a new anti-myeloma agent

Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study, being presented today at the American Association for Cancer Research annual meeting, show the by-product to be more effective than currently used therapies at killing multiple myeloma cells.

16 Apr 2007

Investigational cancer 17-AAG drug targets critical proteins

A drug under study to treat various cancers selectively kills cancer cells because of its affinity for a modified version of a critical heat shock protein they contain, researchers have found.

16 Apr 2007

Prepubertal testicular cancer found to be rare in U.S.

It has been reported that the incidence of testicular cancer in the Caucasian population in the United States increased during most of the last half of the 20th Century, but information on trends in the occurrence of prepubertal testicular cancer is lacking in the literature.

16 Apr 2007

Human Genome Sciences reports results of phase 2b trial of Albuferon

Human Genome Sciences has reported results at Week 12 following the completion of therapy (SVR12) in a Phase 2b clinical trial of Albuferon(R) (albinterferon alfa-2b) in combination with ribavirin in patients with genotype 1 chronic hepatitis C who are naive to interferon alpha-based treatment regimens.

16 Apr 2007